AAAmir H. Ameri

Amir H. Ameri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amir H. Ameri has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lethal Dermal Sarcoma in Immunosuppressed Patients

    by Marjan Azin, Amir H Ameri, Ruth K Foreman, Victor A Neel, Mayra E Lorenzo, Shadmehr Demehri

    Skin cancer is the leading malignancy in immunosuppressed patients, including organ transplant recipients (OTRs), which is increasing in incidence as OTRs live longer. We performed a single-center case series of 4 patients with scalp pleomorphic dermal sarcoma and a history of multiple keratinocyte carcinomas. Outcomes included incidence of dermal sarcoma, dermal sarcoma-related mortality, and histopathologic findings. Out of more than 200 patients followed over a 3-year period in Massachusetts General Hospital High Risk Skin Cancer Clinics, all skin cancer-related deaths (2/2) were due to metastatic dermal sarcoma. Three of 4 patients diagnosed with scalp dermal sarcoma were OTRs and had been on at least one immunosuppressive medication for a median of 9 years. For patients who died from dermal sarcoma, the median time between diagnosis and death was 6 months. Our findings suggest pleomorphic dermal sarcoma contributes to skin cancer-related morbidity and mortality in OTRs.


  • IL-33/Regulatory T-Cell Axis Suppresses Skin Fibrosis

    by Se Yun Cheon, Jong Ho Park, Amir H. Ameri, Richard T. Lee, Rosalynn M. Nazarian, Shadmehr Demehri


  • Open Access

    Hypertrophic Lichen Planus with Histological Features of Squamous Cell Carcinoma Associated with Immune Checkpoint Blockade Therapy

    by Amir H. Ameri, Ruth K. Foreman, Priyanka Vedak, Steven Chen, David M. Miller, Shadmehr Demehri

    Immune checkpoint blockade (ICB) is highly effective for the treatment of metastatic cancers, but its side effects are incompletely understood. The objective of this article is to highlight hypertrophic lichen planus (HLP) with histological features diagnosed as squamous cell carcinoma (SCC), which is a potential cutaneous reaction to ICB. Two patients (75 and 69 years) presented with lesions diagnosed as SCC on biopsy, which developed after 3–9 months on ICB therapy. Biopsies demonstrated endophytic, atypical, or cystic squamous proliferations consistent with cutaneous SCC. However, the clinical presentation including monomorphic nature of the lesions and lichenoid inflammation in the background were consistent with HLP. Patients initially received topical 5-fluorouracil (5-FU) to reduce the hyperkeratotic lesions followed by topical steroids. The eruptions readily responded to this treatment regimen. Dermatologic immune-related adverse events (irAEs) are the most common irAEs associated with ICB therapy. Our findings indicate that HLP resembling SCC on biopsy is a potential side effect of ICB that can be correctly diagnosed on careful clinical exam and is responsive to ICB cessation and topical steroid with or without 5-FU treatment. Key Points: Immune checkpoint blockade is associated with cutaneous immune-related adverse events including lichen planus. Hypertrophic lichen planus can appear as squamous cell carcinoma histologically and clinical context is key for the proper diagnosis. Hypertrophic lichen planus can be safely treated with topical steroids with or without topical 5-fluorouracil in cases with severe hyperkeratotic lesions. Immune checkpoint blockade may be safely continued if clinical presentation is consistent with hypertrophic lichen planus.


  • EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis

    by Lechen Li, Amir H. Ameri, Simeng Wang, Keith H. Jansson, Orla M. Casey, Qi Yang, Michael L. Beshiri, Lei Fang, Ross G. Lake, Supreet Agarwal, et al.

    Early growth response-1 (EGR1) is a transcription factor correlated with prostate cancer (PC) progression in a variety of contexts. For example, EGR1 levels increase in response to suppressed androgen receptor signaling or loss of the tumor suppressor, PTEN. EGR1 has been shown to regulate genes influencing proliferation, apoptosis, immune cell activation, and matrix degradation, among others. Despite this, the impact of EGR1 on PC metastatic colonization is unclear. We demonstrate using a PC model (DU145/RasB1) of bone and brain metastasis that EGR1 expression regulates angiogenic and osteoclastogenic properties of metastases. We have shown previously that FN14 (TNFRSF12A) and downstream NF-κB signaling is required for metastasis in this model. Here we demonstrate that FN14 ligation also leads to NF-κB-independent, MEK-dependent EGR1 expression. EGR1-depletion in DU145/RasB1 cells reduced both the number and size of metastases but did not affect primary tumor growth. Decreased EGR1 expression led to reduced blood vessel density in brain and bone metastases as well as decreased osteolytic bone lesion area and reduced numbers of osteoclasts at the bone–tumor interface. TWEAK (TNFSF12) induced several EGR1-dependent angiogenic and osteoclastogenic factors (e.g., PDGFA, TGFB1, SPP1, IL6, IL8, and TGFA, among others). Consistent with this, in clinical samples of PC, the level of several genes encoding angiogenic/osteoclastogenic pathway effectors correlated with EGR1 levels. Thus, we show here that EGR1 has a direct effect on prostate cancer metastases. EGR1 regulates angiogenic and osteoclastogenic factors, informing the underlying signaling networks that impact autonomous and microenvironmental mechanisms of cancer metastases.


  • Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum

    by A.H. Ameri, M.J. Mooradian, K.S. Emerick, J.C. Park, L.J. Wirth, M.M. Asgari, H. Tsao, D. Lawrence, R.J. Sullivan, S. Demehri


  • Immune neutropenia mediated by micafungin

    by Amir H. Ameri, Brian R. Curtis, David B. Sykes


  • IL-33/regulatory T cell axis triggers the development of a tumor-promoting immune environment in chronic inflammation

    by Amir H. Ameri, Sara Moradi Tuchayi, Anniek Zaalberg, Jong Ho Park, Kenneth H. Ngo, Tiancheng Li, Elena Lopez, Marco Colonna, Richard T. Lee, Mari Mino-Kenudson, et al.

    Chronic inflammation’s tumor-promoting potential is well-recognized; however, the mechanism underlying the development of this immune environment is unknown. Studying the transition from acute, tumor-suppressive to chronic, tumor-promoting allergic contact dermatitis (ACD) revealed how tumor-promoting chronic inflammation develops. Epidermis-derived interleukin (IL)-33 up-regulation and its induction of regulatory T cell (Treg) accumulation in the skin preceded the transition from acute to chronic ACD and triggered the tumor-promoting immune environment in chronic ACD. Mice lacking IL-33 were protected from chronic ACD and its skin cancer sequela compared with wild-type controls (P = 0.0002). IL-33’s direct signaling onto Tregs was required for the development of the tumor-promoting immune environment in the skin. IL-33–Treg signaling was also required for chronic colitis and its associated colorectal cancer development in a colitis model (P < 0.0001). Significantly increased IL-33 and Tregs marked the perilesional skin and colon in patients with cancer-prone chronic inflammatory diseases. Our findings elucidate the role of the IL-33/Treg axis in creating a tumor-promoting immune environment in chronic inflammatory diseases and suggest therapeutic targets for cancer prevention and treatment in high-risk patients. Significance Chronic inflammatory diseases are well-recognized causes of cancer and account for up to 20% of all cancer deaths worldwide. However, the mechanism that initiates the development of a tumor-promoting immune environment in chronic inflammation is not known. Using mouse models of chronic skin and colon inflammation and human samples, we show IL-33 triggers the transition from tumor-suppressive immunity to chronic, tumor-promoting inflammation through a regulatory T cell-dependent mechanism. Our findings demonstrate a generalized dependency of tumor-promoting immune environments on the IL-33/Treg axis both in the skin and colon. Based on these findings, IL-33/Treg axis blockade may be an attractive therapeutic strategy for the treatment and prevention of cancers associated with chronic inflammatory diseases and potentiating the antitumor immunity induced by cancer immunotherapeutics.


  • Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus

    by Anniek Zaalberg, Sara Moradi Tuchayi, Amir H. Ameri, Kenneth H. Ngo, Trevor J. Cunningham, Jean-Pierre Eliane, Maia Livneh, Thomas D. Horn, Ilana S. Rosman, Amy Musiek, et al.


  • Open Access

    Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors

    by Supreet Agarwal, Paul G. Hynes, Heather S. Tillman, Ross Lake, Wassim G. Abou-Kheir, Lei Fang, Orla M. Casey, Amir H. Ameri, Philip L. Martin, Juan Juan Yin, et al.


  • Open Access

    Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis

    by Yen-Nien Liu, JuanJuan Yin, Ben Barrett, Heather Sheppard-Tillman, Dongmei Li, Orla M. Casey, Lei Fang, Paul G. Hynes, Amir H. Ameri, Kathleen Kelly

    Bone metastasis is the hallmark of progressive and castration resistant prostate cancers. miR-1 levels are decreased in clinical samples of primary prostate cancer and further reduced in metastases. SRC has been implicated as a critical factor in bone metastasis, and here we show that SRC is a direct target of miR-1. In prostate cancer patient samples, miR-1 levels are inversely correlated with SRC expression and a SRC dependent gene signature. Ectopic miR-1 expression inhibited ERK signaling and bone metastasis in a xenograft model. In contrast, SRC overexpression was sufficient to reconstitute bone metastasis and ERK signaling in cells expressing high levels of miR-1. AR activity, defined by an AR output signature, is low in a portion of castration resistant prostate cancer. We show that AR binds to the miR-1-2 regulatory region, and regulates miR-1 transcription. Patients with low miR-1 levels displayed correlated low canonical AR gene signatures. Our data support the existence of an AR, miR-1, SRC regulatory network. We propose that loss of miR-1 is one mechanistic link between low canonical AR output and SRC promoted metastatic phenotypes.